7th November 2019

Mirada Medical Announces New Wave of Global Installations of World-First Artificial Intelligence Software for Cancer Treatment – DLCExpert™

Announcement builds on Mirada Medical’s FDA clearance of DLCExpert™ in 2018, making it the only deep learning autocontouring system with one year of clinically approved experience

 Oxford, United Kingdom, November 7, 2019 – Mirada Medical, a global leader in Artificial Intelligence (AI) software for the treatment of cancer, has announced today further global installations of DLCExpert™, the world’s first commercially available AI-powered autocontouring software for cancer treatment planning and the only system with over one year of clinically proven use.

Mirada’s advanced software products targeting cancer care are in daily clinical use at over 1,400 hospitals worldwide and its breakthrough DLCExpert AI system has been recently deployed at multiple global centers of clinical excellence including Moffitt Cancer Center, Mayo Clinic, UMC Groningen, and The Christie NHS Foundation Trust.

The company has today announced further installations at leading cancer centers in the United States and Europe including Northwestern Hospital (IL), City of Hope (CA), CHU Liège, and Royal Surrey NHS Foundation Trust.

Dr. Amato J. Giaccia, Director of the Institute of Radiation Oncology at Oxford University and  Chairperson of the Mirada Medical Strategic Advisory Board said: “With Mirada Medical’s  deployments of DLCExpert now benefiting cancer patients globally and on a daily basis , I couldn’t be more excited to be a part of this exciting company as Chairman of the Strategic Medical Advisory Board.”

 Dr Giaccia continued “I believe that automated contouring of organs at risk (OARs) using AI is revolutionizing the radiotherapy planning process. Not only can AI free up doctors’ time, which is a huge benefit for patients, but it may also enable better outcomes.”

 “This is not just about producing faster workflows, it’s also about the overall quality of treatment plans, as AI will be able to help identify normal tissue and preserve at risk tissue. This, in turn, will help deliver greater personalised care, while potentially contributing to improved outcomes.”

These milestone achievements track alongside a continually growing body of clinical evidence, produced in partnership with global academic medical partners, that underlines the real-word benefit obtained by clinics who have deployed the world-first deep learning autocontouring system, Mirada’s DLCExpert™. In particular, multiple published clinical studies provide robust evidence which confirms that software generated contours, reviewed and refined by clinicians, represent a viable strategy for reducing contouring time while also reinforcing compliance with established clinical standards. Research published by the American Association of Physicists in medicine has indicated time savings of up to 77% for some organs, resulting from editing software generated contours compared to the standard clinical workflow.

Charlotte Brouwer, Medical Physicist at the Department of Radiation Oncology, University Medical Center Groningen, said: “The collaboration between UMC Groningen and Mirada Medical has produced autocontouring models that encode according to consensus guidelines, established by an international panel of experts for organs at risk. These DLCExpert models are now deployed in our routine clinical workflows, forming a key part of our treatment planning for all patients with cancers in the head and neck or prostate regions.”

 “Thanks to DLCExpert, we now enjoy measurable and consistent time-savings, which we expect to translate to other institutions. Perhaps the clearest indications of their clinical acceptance were the loud objections of our RT planning team when the models were briefly unavailable during routine maintenance!”

 Mirada Medical CEO, Hugh Bettesworth said: “I am delighted that Mirada’s technology is being deployed so widely and that patients are benefitting from it every day. We hear a lot of talk about bringing artificial intelligence to medicine - I am immensely proud that it is Mirada’s brilliant team of scientists and engineers who have worked with our customers, our clinical advisors, and the regulators in the USA and Europe, and have delivered every-patient clinical advances for cancer treatment planning using artificial intelligence.”

- ENDS -

Mirada Medical, DLCExpert, RTx and Workflow Box are trademarks of Mirada Medical Ltd.


About Mirada Medical

Mirada Medical is a leading international brand in medical imaging. The company develops advanced technology applications that help healthcare professionals use medical images more effectively and efficiently to improve cancer care. Mirada’s products are used across diagnostic radiology, molecular imaging, radiation oncology, medical oncology, tumor board and elsewhere.

The company specializes in simplifying technically complex image processing tasks, allowing clinicians to more confidently diagnose disease, assess response to treatment, and plan radiation therapy or surgical intervention. Mirada’s advanced technology products are available throughout the world under its own brand, and on an OEM basis through a select number of the world’s leading healthcare companies.

About Mirada Medical’s Strategic Advisory Board

Mirada Medical’s Strategic Advisory Board has been assembled to drive forward its clinical strategy for the deployment of AI in the treatment of cancer. The Board, chaired by Dr. Amato J. Giaccia, Director of the Institute of Radiation Oncology at Oxford University - is composed of accomplished leaders in the field of radiation oncology and medical imaging with appointments including:


  • Thomas Buchholz, M.D., Medical Director of the Scripps MD Anderson Cancer Center
  • Dan Fass, CEO of Princeton Healthcare Alliance (PHA)
  • Carlo Greco, Director of Clinical Research at the Champalimaud Centre for the Unknown (CCU)
  • Penny Kechagioglou, Chief Medical Officer at Genesis Care UK
  • Philip Poortsmans, M.D., PhD, Head of the Department of Radiation Oncology at the Institut Curie
  • Marc Posner, Medical Director of the Department of Radiation Oncology at Nortwestern Lake Forest Hospital


For more information, please contact:

Annamaria Albano

Mirada Medical Ltd Annamaria.albano@mirada-medical.com